Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 12Unknown 5Terminated 3Recruiting 3Withdrawn 1Suspended 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1NET 1Endocrine 1

Conditions

Leukemia, Myeloid, Acute 19Breast Neoplasms 17Advanced Solid Tumors 16Advanced Solid Tumor 12Carcinoma, Non-Small-Cell Lung 10Myelodysplastic Syndromes 9Uterine Cervical Neoplasms 6Solid Tumor 6Recurrence 6Prostatic Neoplasms 6Lymphoma, Large B-Cell, Diffuse 6Triple Negative Breast Neoplasms 5Stomach Neoplasms 5Ovarian Neoplasms 5Carcinoma, Hepatocellular 5Small Cell Lung Carcinoma 4Myeloproliferative Disorders 4Multiple Myeloma 4Advanced Solid Tumour 4Advanced Malignant Solid Tumor 4Solid Tumors 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Lymphoma, Non-Hodgkin 3Lymphoma 3Leukemia, Myelomonocytic, Chronic 3Biliary Tract Neoplasms 3Advanced Lung Cancer 3Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2

Interventions

pembrolizumab 38Blood Specimen Collection 38Bevacizumab 22Surveys and Questionnaires 18Standard of Care 18Radiotherapy 17Exercise 17Carboplatin 17Nivolumab 15atezolizumab 14Paclitaxel 14Cisplatin 14Drug Therapy 13Fluorouracil 12Cyclophosphamide 12Cetuximab 11Trastuzumab 10Pemetrexed 10Leucovorin 10Docetaxel 10Dexamethasone 10Oxaliplatin 9Biopsy 9pertuzumab 8olaparib 8Temozolomide 8Panitumumab 8Observation 8Irinotecan 8abemaciclib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Neoplasms × Injections × Clear all
NCT07002034 2026-05-06

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

Reunion Neuroscience Inc

Phase 2 Recruiting
100 enrolled

Adjustment Disorders, Amyotrophic Lateral Sclerosis, Anxiety Disorders, Depression, Multiple Sclerosis, Neoplasms, Idiopathic Pulmonary Fibrosis

NCT07112222 2026-01-26

A Study of LM-350 in Subjects With Advanced Solid Tumours

LaNova Medicines Limited

Phase 1/2 Recruiting
80 enrolled
Tumor-Agnostic

Neoplasms

NCT04837885 2025-07-23

LUTARTERIAL

University Hospital, Bordeaux

Phase 2 Recruiting
23 enrolled
EndocrineNET

Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡